In Section A, members will acquire unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will probably be enrolled for the identified monotherapy dosign regimen. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Phase https://clinical-trial-recruitmen58912.bloggadores.com/31428156/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy